
SENATE FLOOR AMENDMENTS

2026 Regular Session

Amendments proposed by Senator Talbot to Engrossed Senate Bill No. 401 by Senator Talbot

1 AMENDMENT NO. 1

2 On page 3, between lines 12 and 13, insert the following:

3 **"(7) "Research and development expenditures" means all costs that a**
4 **pharmaceutical manufacturer incurs during a calendar year that relate to the**
5 **research and development of products, processes, or services and includes the**
6 **costs of research and development of products, processes, or services that the**
7 **pharmaceutical manufacturer has acquired or obtained via a license.**

8 **(8) Wholesale acquisition cost or "WAC" has the same meaning as**
9 **provided in 42 U.S.C. 1395w-3a(c)(6)(B)."**

10 AMENDMENT NO. 2

11 On page 3, between lines 23 and 24, insert the following:

12 **"(7) One member of a patient advocacy group, appointed by the**
13 **commissioner."**

14 AMENDMENT NO. 3

15 On page 4, between lines 11 and 12, insert the following:

16 **"I. A member, or his designee, shall not be an employee of, a board**
17 **member of, or a consultant to a manufacturer, pharmacy benefit manager,**
18 **health insurance carrier, health maintenance organization, managed care**
19 **organization, or wholesale distributor or related trade association.**

20 **J. Any conflict of interest, including a financial or personal association,**
21 **that has the potential to bias or has the appearance of biasing an individual's**
22 **decision in matters related to the board or the conduct of the board's activities**
23 **shall be considered and disclosed when appointing members, or a member's**
24 **designee, to the board."**

25 AMENDMENT NO. 4

26 On page 4, at the beginning of line 12, change "I." to "K."